Search results for " RELAP"

showing 10 items of 130 documents

Studio con il codice RELAP5 delle perdite di carico e dello scambio termico in tubi elicoidali interessati da deflussi monofase

2009

codice RELAP5 perdite di carico deflussi monofase
researchProduct

Modifiche al codice RELAP5 per l’analisi termofluidodinamica monofase delle perdite di carico in scambiatori di calore a tubi elicoidali

2009

codice RELAP5 perdite di caricotubi elicoidali
researchProduct

Qualifica di codici di calcolo dedicati alle analisi di sistema avanzati quando applicati nella simulazione di impianti a metallo liquido

2013

generation iv relap termofluidodinamica avanzataSettore ING-IND/19 - Impianti Nucleari
researchProduct

Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in post-operative Crohn's disease

2008

Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Renna S, Cammà C, Modesto I, Cabibbo G, Scimeca D, Civitavecchia G, Mocciaro F, Orlando A, Enea M, Cottone M. Dipartimento di Medicina, Pneumologia e Fisiologia della Nutrizione Umana, Università di Palermo, Palermo, Italy. BACKGROUNDS & AIMS: The benefit of therapy for prevention of postoperative recurrence of Crohn's disease (CD) is limited. Clinical relapse and severe endoscopic recurrence are the main outcomes in the evaluation of trials on prevention of recurrence. The aim of this meta-analysis was to focus on knowledge of the placebo rates of relapse and recurr…

medicine.medical_specialtyMEDLINEDiseasePlaceboEndoscopy Gastrointestinallaw.inventionCrohn DiseaseRandomized controlled triallawInternal medicineSecondary PreventionmedicineHumansPostoperative PeriodDigestive System Surgical ProceduresRandomized Controlled Trials as TopicCrohn's diseaseHepatologybusiness.industryGastroenterologyOdds ratioPrognosismedicine.diseaseConfidence intervalSurgeryMeta-analysisMeta-analysis placebo relapse severe endoscopic recurrencebusiness
researchProduct

Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.

2021

Objective: To identify baseline factors associated with disease activity in patients with relapsing–remitting multiple sclerosis (RRMS) under teriflunomide treatment. Methods: This was an independent, multi-centre, retrospective post-marketing study. We analysed data of 1,507 patients who started teriflunomide since October 2014 and were regularly followed in 28 Centres in Italy. We reported the proportions of patients who discontinued treatment (after excluding 32 lost to follow-up) and who experienced clinical disease activity, i.e., relapse(s) and/or confirmed disability worsening, as assessed by the Expanded Disability Status Scale (EDSS). Decision tree-based analysis was performed to i…

medicine.medical_specialtyNeurologyMultiple SclerosisToluidinesHydroxybutyratesOral drugsDiseaseRelapsing-RemittingSettore MED/26Pregnancy planning03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicineTeriflunomideTeriflunomideNitrilesmedicineHumans030212 general & internal medicineAdverse effectRetrospective StudiesExpanded Disability Status Scalebusiness.industryMultiple sclerosismedicine.diseaseSettore MED/26 - NEUROLOGIANeurologychemistryTolerabilityItalyMultiple sclerosis; Oral drugs; Teriflunomide; Crotonates; Humans; Hydroxybutyrates; Italy; Nitriles; Retrospective Studies; Toluidines; Multiple Sclerosis; Multiple Sclerosis Relapsing-RemittingCrotonatesNeurology (clinical)business030217 neurology & neurosurgeryJournal of neurology
researchProduct

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

2011

Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficacious in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

medicine.medical_specialtyPediatricspml; iris; multiple sclerosis; natalizumabMultiple SclerosisNeurologypmlMEDLINEProgressive MultifocalDermatologyRelapsing-RemittingAntibodies Monoclonal HumanizedAntibodiesLeukoencephalopathyMultiple Sclerosis Relapsing-RemittingNatalizumabLeukoencephalopathyMonoclonalmedicineHumansAdverse effectAntibodies; Monoclonal; Humanized Antibodies; therapeutic use Humans Leukoencephalopathy; Progressive Multifocal; chemically induced Multiple Sclerosis; Relapsing-Remitting; drug therapyHumanizedMultiple sclerosis Natalizumab PML IRISirisbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisLeukoencephalopathy Progressive MultifocalAntibodies MonoclonalGeneral Medicinemedicine.diseasedrug therapyPsychiatry and Mental healththerapeutic usechemically inducednatalizumab multiple sclerosis treatment guidelinesPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusinessmedicine.drug
researchProduct

Uveítis anterior aguda hipertensiva granulomatosa bilateral como efecto adverso a brimonidina tópica

2018

Abstract Clinical case The case concerns an 81-year-old woman on treatment with a topical fixed combination of timolol and brimonidine who was diagnosed in the Emergency Department with acute anterior granulomatous hypertensive uveitis. The patient responded favorably to the withdrawal of the eye drops without showing any subsequent relapse. Discussion Uveitis due to brimonidine is a rare adverse effect, but it must be known. Once the diagnosis is suspected, the effective treatment is the withdrawal of brimonidine, with or without the addition of topical corticosteroids to control inflammation depending on the severity of the condition. It is a process with an excellent prognosis.

medicine.medical_specialtySubsequent RelapseSide effectbusiness.industryBrimonidineTimololEmergency departmentmedicine.diseaseDermatology03 medical and health sciencesOphthalmology0302 clinical medicine030221 ophthalmology & optometrymedicineAnterior uveitisAdverse effectbusiness030217 neurology & neurosurgeryUveitismedicine.drugArchivos de la Sociedad Española de Oftalmología
researchProduct

Fourth case of louse-borne relapsing fever in Young Migrant, Sicily, Italy, December 2015. Mini Review Article

2016

Abstract Objectives Currently louse-borne relapsing fever (LBRF) is primarily found in limited endemic foci in Ethiopia, Somalia and Sudan; no case of imported LBRF has been reported in Europe in the 9 years prior to 2015. The aim of our paper is to describe a new case of imported LBRF detected in Sicily, Italy, and to review all cases reported in migrants arrived in Europe in the last 10 years. Study design Mini review of all published cases of louse-borne relapsing fever in Europe in the last 10 years. Methods A computerized search without language restriction was conducted using PubMed combining the terms ‘(louse-borne relapsing fever or LBRF or recurrentis) and (refugee or Europe or mig…

myalgiaAdultMalemedicine.medical_specialtyPediatricsRefugeerelapsing feverSomalia030231 tropical medicineDiagnosis Differential03 medical and health sciences0302 clinical medicineEpidemiologyBorrelia recurrentis; Europe; Louse-borne relapsing fever; Refugees; Public Health Environmental and Occupational HealthmedicineHumans030212 general & internal medicineLouse-Borne Relapsing FeverSicilyTransients and MigrantsLouse-borne relapsing feverbiologyBorrelia recurrentibusiness.industryPublic healthBorreliaRelapsing FeverPublic Health Environmental and Occupational HealthGeneral MedicineLice Infestationsmedicine.diseasebiology.organism_classificationEuropeFamily medicineChillsmedicine.symptomHeadachesbusinessBorrelia recurrentis
researchProduct

Off-Adherence Keeping (OAK) observational study: intentional off-adherence immunomodulatory multiple sclerosis treatment

2022

Aims: To evaluate how improved treatment adherence with a lower-frequency regimen/treatment of intramuscular (IM) IFN beta-1a impacts therapeutic effectiveness in relapsing-remitting multiple sclerosis (MS) patients switching from a higher-frequency injectable regimen/treatment. Patients & methods: Italian patients with relapsing-remitting MS and prior poor adherence to high-frequency injectable treatments (n = 181) were followed for 24 months after starting IM IFN beta-1a. Results: During the study, 97.4% of patients were treatment adherent; 22.1% of patients reported a relapse. The estimated probability of remaining relapse-free after 2 years was 78%. A high dropout rate (52.5%) led t…

relapsesMultiple Sclerosis Relapsing-RemittingTreatment Outcomequality of lifeRecurrenceHumansSettore MED/26 - NeurologiaInterferon-betaNeurology (clinical)multiple sclerosistreatment adherenceInterferon beta-1aintramuscular interferon beta-1aNeurodegenerative Disease Management
researchProduct

Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with …

2019

ObjectiveOur aim was to summarize the efficacy and safety of atomoxetine, amphetamines, and methylphenidate in schizophrenia.MethodsWe undertook a systematic review, searching PubMed/Scopus/Clinicaltrials.gov for double-blind, randomized, placebo-controlled studies of psychostimulants or atomoxetine in schizophrenia published up to 1 January 2017. A meta-analysis of outcomes reported in two or more studies is presented.ResultsWe included 22 studies investigating therapeutic effects of stimulants (k=14) or measuring symptomatic worsening/relapse prediction after stimulant challenge (k=6). Six studies of these two groups plus one additional study investigated biological effects of psychostimu…

safetymedicine.medical_specialtyPsychosismedicine.medical_treatmentefficacyamphetamineSchizoaffective disorderAtomoxetine Hydrochloridemeta-analysi03 medical and health sciencesExecutive Function0302 clinical medicinesystematic reviewInternal medicinemedicineHumansAttentionAmphetamineProblem Solvingbusiness.industryMethylphenidateAtomoxetineAmphetaminesrelapse predictorstimulantmedicine.disease030227 psychiatryStimulantPsychiatry and Mental healthMemory Short-Termamphetamine atomoxetine efficacy meta-analysis methylphenidate relapse predictor safety schizophrenia stimulants systematicn reviewPsychotic DisordersSchizophreniaMeta-analysisMethylphenidateSchizophreniaNeurology (clinical)businessatomoxetine030217 neurology & neurosurgerymedicine.drugAntipsychotic Agents
researchProduct